<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01456780</url>
  </required_header>
  <id_info>
    <org_study_id>11-048H</org_study_id>
    <nct_id>NCT01456780</nct_id>
  </id_info>
  <brief_title>Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis</brief_title>
  <acronym>ZvL</acronym>
  <official_title>Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blepharitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IV, single site, randomized, double masked, parallel control clinical trial
      of 60 subjects to investigate the variance of efficacy between Lotemax® and Zylet® for
      treatment of ocular surface inflammation due to meibomian gland dysfunction (MGD). Efficacy
      will be measured by in-vivo confocal microscopy, corneal fluorescein staining, grading of
      meibomian gland dysfunction and validated ocular symptom assessment questionnaire.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Posterior blepharitis is a common chronic eyelid condition that is described as generalized
      inflammation of the posterior lid margin and associated with inflammation of the ocular
      surface and with symptoms of burning, irritation, and discomfort. Posterior blepharitis is
      associated with various disorders of the meibomian glands, known collectively as meibomian
      gland dysfunction (MGD). It is associated either with obstruction and inflammation of the
      meibomian glands or, less commonly, atrophy of the meibomian glands.

      Clinically, MGD often presents with inspissated meibomian glands, oily tear film, as well as
      inflammation and vascularization of the meibomian gland orifices. Papillary hypertrophy of
      the tarsal conjunctiva and corneal punctate epitheliopathy are often present, and there are
      prominent associations with dermatoses, such as acne rosacea, seborrhoeic dermatitis, and
      atopic dermatitis. Evidence from several sources suggests that MGD of sufficient extent and
      degree is associated with a deficient tear lipid layer, an increase in tear evaporation, and
      the occurrence of an evaporative dry eye. In fact MGD is considered to be the most common
      cause of evaporative dry eye. Individuals with MGD often complain of significant discomfort,
      including burning, itching, irritation, and photophobia. They may also have other associated
      symptoms of dry eye and may be plagued by blurred vision, gradual contact lens intolerance.
      Furthermore, these patients may become functionally handicapped by the negative impact of dry
      eye on their crucial daily activities such as working, reading, using computer, and driving.

      Despite the high incidence of posterior blepharitis, there is currently no consistently
      effective treatment for this condition and it still remains a therapeutic challenge.
      Posterior blepharitis has traditionally been managed with eyelid hygiene, topical antibiotics
      (erythromycin or bacitracin ointments), oral tetracyclines (tetracycline, doxycycline, or
      minocycline) and corticosteroids which are often time consuming, frustrating, and frequently
      ineffective or variably effective.

      The purpose of this study is to compare the effectiveness of topical loteprednol
      (corticosteroid) vs. the combination of loteprednol and tobramycin (corticosteroid and
      antibiotic) against an artificial tear. It is critical to determine to what extent the
      addition of an antibiotic to a topical steroid can enhance the therapeutic efficacy of the
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2011</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Surface Disease Index</measure>
    <time_frame>Week 4 Time Point</time_frame>
    <description>OSDI is a 12-question survey used to measure the symptoms of dry eye disease. Each of the 12 individual questions rate one symptom on a 0-4 scale, with 4 meaning that the symptom is present all of the time and 0 meaning the symptom is present none of the time. The overall ODSI score is calculated by adding all of the values from the 12 questions, multiplying that value by 25, and dividing the resulting value by the number of questions answered. This results in an overall scale that ranges from 0-100, with 100 being severe dry eye symptoms and 0 being no dry eye symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom Assessment iN Dry Eye (SANDE) Frequency Score</measure>
    <time_frame>Week 4 Time Point</time_frame>
    <description>Questionnaire given to patients to assess the frequency of dry eye symptoms. The questionnaire utilizes a 100 mm horizontal Visual Analogue Scale technique to quantify the frequency of the patient's dry eye symptoms. Change is quantified from baseline to week 4. The range of the SANDE frequency scale is 0-100, with 0 being the minimum level of frequency of dry eye symptoms and 100 being the maximum level of frequency of dry eye symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom Assessment iN Dry Eye (SANDE) Severity Score</measure>
    <time_frame>Week 4 Time Point</time_frame>
    <description>Questionnaire given to patients to assess the severity of dry eye symptoms. The questionnaire utilizes a 100 mm horizontal Visual Analogue Scale technique to quantify the severity of the patient's dry eye symptoms. Change is quantified from baseline to week 4. The range of the SANDE severity scale is 0-100, with minimum level of severity of dry eye symptoms and 100 being the maximum level of severity of dry eye symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Fluorescein Staining Score</measure>
    <time_frame>Week 4 Time Point</time_frame>
    <description>Corneal Fluorescein Staining is used to assess the level of corneal epitheliopathy that is related to dry eye disease. The CFS scale ranges from 0 to 15 scale, with 0 representing the minimum level of corneal epitheliopathy and 15 representing the maximum level of corneal epitheliopathy.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <condition>Posterior Blepharitis</condition>
  <arm_group>
    <arm_group_label>Zylet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject randomized to this arm will be treated with Zylet (Loteprednol/tobramycin), twice a day, for 4 weeks. Zylet is a combination of loteprednol and tobramycin. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation. Tobramycin is an antibiotic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lotemax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject randomized to this arm will be treated with Lotemax, twice a day, for 4 weeks. Lotemax is also known as loteprednol. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B+L Advanced Eye Relief Lubricant Drop</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject randomized to this arm will be treated with B+L Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), twice a day, for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol/tobramycin</intervention_name>
    <description>Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.</description>
    <arm_group_label>Zylet</arm_group_label>
    <other_name>Zylet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol</intervention_name>
    <description>Eye drops, 1 drop twice a day for 4 weeks</description>
    <arm_group_label>Lotemax</arm_group_label>
    <other_name>Lotemax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B+L Advanced Eye Relief Lubricant Drop</intervention_name>
    <description>Bausch + Lomb (B+L) Advanced Eye Relief Lubricant Drop (Artificial Tears), 1 drop twice a day for 4 weeks.</description>
    <arm_group_label>B+L Advanced Eye Relief Lubricant Drop</arm_group_label>
    <other_name>artificial tears</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  At least 18 years of age

          -  Has not worn contact lenses, except for bandage contact lens or rigid gas permeable
             lens, for at least 2 weeks prior to the study and agrees to not wear contact lenses
             during study

          -  Patient is in generally good &amp; stable overall health

          -  Minimum corneal fluorescein staining of 4 in at least one eye

          -  OSDI score &gt;22

          -  The patient must have a diagnosis of posterior blepharitis

          -  A negative urine pregnancy test result for women of childbearing potential

          -  Women of childbearing potential must agree to use adequate contraception (hormonal or
             barrier method of birth control) prior to study entry and for the duration of study
             participation.

          -  Normal lid position and closure

          -  Ability to understand and provide informed consent to participate in this study

          -  Willingness to follow study instructions and likely to complete all required visits

        Exclusion Criteria:

          -  History of Stevens-Johnson syndrome or ocular pemphigoid

          -  History of eyelid surgery

          -  Intra-ocular surgery or ocular laser surgery within 3 months

          -  History of microbial keratitis, including herpes

          -  Active ocular allergies

          -  Corneal epithelial defect &gt; 1mm2

          -  Any change in use of topical anti-inflammatories, such as steroids, Restasis, or NSAID
             within the past 2 weeks

          -  Any change in dosage of tetracycline compounds (tetracycline, doxycycline, and
             minocycline) within the past two weeks

          -  Use of isotretinoin (Accutane) within the past 6 months

          -  Pregnant or lactating women

          -  Signs of current infection, including fever and current treatment with antibiotics

          -  Active liver, renal, or hematologic disease

          -  The use of any other investigational drug

          -  Individuals with a known history of glaucoma, individuals with IOP &gt;22 Hg in either
             eye and individuals with a known family history of glaucoma in primary (first degree)
             relatives (ie. mother, father, sibling or child)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Dana, MD, MPH, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear Infirmary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts Eye &amp; Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2011</study_first_submitted>
  <study_first_submitted_qc>October 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2011</study_first_posted>
  <results_first_submitted>April 6, 2017</results_first_submitted>
  <results_first_submitted_qc>May 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2017</results_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Reza Dana, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Meibomian gland dysfunction</keyword>
  <keyword>Blepharitis</keyword>
  <keyword>Dry Eye</keyword>
  <keyword>Ocular Inflammation</keyword>
  <keyword>MGD</keyword>
  <keyword>Zylet</keyword>
  <keyword>Lotemax</keyword>
  <keyword>Artificial Tear</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zylet</title>
          <description>Subject randomized to this arm will be treated with Zylet, twice a day, for 4 weeks. Zylet is a combination of loteprednol and tobramycin. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation. Tobramycin is an antibiotic.
Loteprednol/tobramycin: Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Lotemax</title>
          <description>Subject randomized to this arm will be treated with Lotemax, twice a day, for 4 weeks. Lotemax is also known as loteprednol. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation.
Loteprednol: Eye drops, 1 drop twice a day for 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Bausch &amp; Lomb Lubricant Drops</title>
          <description>Subject randomized to this arm will be treated with artificial tears, twice a day, for 4 weeks.
Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops: Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), 1 drop twice a day for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zylet</title>
          <description>Subject randomized to this arm will be treated with Zylet, twice a day, for 4 weeks. Zylet is a combination of loteprednol and tobramycin. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation. Tobramycin is an antibiotic.
Loteprednol/tobramycin: Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Lotemax</title>
          <description>Subject randomized to this arm will be treated with Lotemax, twice a day, for 4 weeks. Lotemax is also known as loteprednol. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation.
Loteprednol: Eye drops, 1 drop twice a day for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Bausch &amp; Lomb Lubricant Drops</title>
          <description>Subject randomized to this arm will be treated with artificial tears, twice a day, for 4 weeks.
Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops: Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), 1 drop twice a day for 4 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="13"/>
                    <measurement group_id="B2" value="52" spread="12"/>
                    <measurement group_id="B3" value="57" spread="12"/>
                    <measurement group_id="B4" value="55" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ocular Surface Disease Index</title>
          <description>The Ocular Surface Disease Index score ranges from 0-100, with 100 being severe dry eye symptoms and 0 being no dry eye symptoms</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.7" spread="18.0"/>
                    <measurement group_id="B2" value="52.0" spread="22.6"/>
                    <measurement group_id="B3" value="57.0" spread="21.3"/>
                    <measurement group_id="B4" value="56.3" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptom Assessment in Dry Eye (SANDE) Frequency Score</title>
          <description>The range of the SANDE frequency scale is 0-100, with 0 being the minimum level of frequency of dry eye symptoms and 100 being the maximum level of frequency of dry eye symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.8" spread="14.2"/>
                    <measurement group_id="B2" value="60.9" spread="19.4"/>
                    <measurement group_id="B3" value="68.1" spread="17.8"/>
                    <measurement group_id="B4" value="68.9" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptom Assessment in Dry Eye (SANDE) Severity Score</title>
          <description>The range of the SANDE frequency scale is 0-100, with 0 being the minimum level of severity of dry eye symptoms and 100 being the maximum level of severity of dry eye symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.0" spread="19.8"/>
                    <measurement group_id="B2" value="58.1" spread="19.6"/>
                    <measurement group_id="B3" value="64.2" spread="19.5"/>
                    <measurement group_id="B4" value="63.2" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corneal Fluorescein Staining (CFS)</title>
          <description>The CFS scale ranges from 0 to 15 scale, with 0 representing the minimum level of corneal epitheliopathy and 15 representing the maximum level of corneal epitheliopathy.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.8" spread="2.6"/>
                    <measurement group_id="B2" value="6.6" spread="2.5"/>
                    <measurement group_id="B3" value="6.1" spread="2.0"/>
                    <measurement group_id="B4" value="6.5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Surface Disease Index</title>
        <description>OSDI is a 12-question survey used to measure the symptoms of dry eye disease. Each of the 12 individual questions rate one symptom on a 0-4 scale, with 4 meaning that the symptom is present all of the time and 0 meaning the symptom is present none of the time. The overall ODSI score is calculated by adding all of the values from the 12 questions, multiplying that value by 25, and dividing the resulting value by the number of questions answered. This results in an overall scale that ranges from 0-100, with 100 being severe dry eye symptoms and 0 being no dry eye symptoms.</description>
        <time_frame>Week 4 Time Point</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zylet</title>
            <description>Subject randomized to this arm will be treated with Zylet, twice a day, for 4 weeks. Zylet is a combination of loteprednol and tobramycin. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation. Tobramycin is an antibiotic.
Loteprednol/tobramycin: Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lotemax</title>
            <description>Subject randomized to this arm will be treated with Lotemax, twice a day, for 4 weeks. Lotemax is also known as loteprednol. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation.
Loteprednol: Eye drops, 1 drop twice a day for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Bausch &amp; Lomb Lubricant Drops</title>
            <description>Subject randomized to this arm will be treated with artificial tears, twice a day, for 4 weeks.
Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops: Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), 1 drop twice a day for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Surface Disease Index</title>
          <description>OSDI is a 12-question survey used to measure the symptoms of dry eye disease. Each of the 12 individual questions rate one symptom on a 0-4 scale, with 4 meaning that the symptom is present all of the time and 0 meaning the symptom is present none of the time. The overall ODSI score is calculated by adding all of the values from the 12 questions, multiplying that value by 25, and dividing the resulting value by the number of questions answered. This results in an overall scale that ranges from 0-100, with 100 being severe dry eye symptoms and 0 being no dry eye symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6" spread="22.4"/>
                    <measurement group_id="O2" value="46.4" spread="24.8"/>
                    <measurement group_id="O3" value="48.4" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Symptom Assessment iN Dry Eye (SANDE) Frequency Score</title>
        <description>Questionnaire given to patients to assess the frequency of dry eye symptoms. The questionnaire utilizes a 100 mm horizontal Visual Analogue Scale technique to quantify the frequency of the patient’s dry eye symptoms. Change is quantified from baseline to week 4. The range of the SANDE frequency scale is 0-100, with 0 being the minimum level of frequency of dry eye symptoms and 100 being the maximum level of frequency of dry eye symptoms.</description>
        <time_frame>Week 4 Time Point</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zylet</title>
            <description>Subject randomized to this arm will be treated with Zylet, twice a day, for 4 weeks. Zylet is a combination of loteprednol and tobramycin. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation. Tobramycin is an antibiotic.
Loteprednol/tobramycin: Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lotemax</title>
            <description>Subject randomized to this arm will be treated with Lotemax, twice a day, for 4 weeks. Lotemax is also known as loteprednol. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation.
Loteprednol: Eye drops, 1 drop twice a day for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Bausch &amp; Lomb Lubricant Drops</title>
            <description>Subject randomized to this arm will be treated with artificial tears, twice a day, for 4 weeks.
Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops: Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), 1 drop twice a day for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Assessment iN Dry Eye (SANDE) Frequency Score</title>
          <description>Questionnaire given to patients to assess the frequency of dry eye symptoms. The questionnaire utilizes a 100 mm horizontal Visual Analogue Scale technique to quantify the frequency of the patient’s dry eye symptoms. Change is quantified from baseline to week 4. The range of the SANDE frequency scale is 0-100, with 0 being the minimum level of frequency of dry eye symptoms and 100 being the maximum level of frequency of dry eye symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.9" spread="28.9"/>
                    <measurement group_id="O2" value="51.7" spread="23.3"/>
                    <measurement group_id="O3" value="50.5" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Symptom Assessment iN Dry Eye (SANDE) Severity Score</title>
        <description>Questionnaire given to patients to assess the severity of dry eye symptoms. The questionnaire utilizes a 100 mm horizontal Visual Analogue Scale technique to quantify the severity of the patient’s dry eye symptoms. Change is quantified from baseline to week 4. The range of the SANDE severity scale is 0-100, with minimum level of severity of dry eye symptoms and 100 being the maximum level of severity of dry eye symptoms.</description>
        <time_frame>Week 4 Time Point</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zylet</title>
            <description>Subject randomized to this arm will be treated with Zylet, twice a day, for 4 weeks. Zylet is a combination of loteprednol and tobramycin. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation. Tobramycin is an antibiotic.
Loteprednol/tobramycin: Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lotemax</title>
            <description>Subject randomized to this arm will be treated with Lotemax, twice a day, for 4 weeks. Lotemax is also known as loteprednol. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation.
Loteprednol: Eye drops, 1 drop twice a day for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Bausch &amp; Lomb Lubricant Drops</title>
            <description>Subject randomized to this arm will be treated with artificial tears, twice a day, for 4 weeks.
Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops: Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), 1 drop twice a day for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Assessment iN Dry Eye (SANDE) Severity Score</title>
          <description>Questionnaire given to patients to assess the severity of dry eye symptoms. The questionnaire utilizes a 100 mm horizontal Visual Analogue Scale technique to quantify the severity of the patient’s dry eye symptoms. Change is quantified from baseline to week 4. The range of the SANDE severity scale is 0-100, with minimum level of severity of dry eye symptoms and 100 being the maximum level of severity of dry eye symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.5" spread="25.8"/>
                    <measurement group_id="O2" value="54.4" spread="20.2"/>
                    <measurement group_id="O3" value="51.2" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Fluorescein Staining Score</title>
        <description>Corneal Fluorescein Staining is used to assess the level of corneal epitheliopathy that is related to dry eye disease. The CFS scale ranges from 0 to 15 scale, with 0 representing the minimum level of corneal epitheliopathy and 15 representing the maximum level of corneal epitheliopathy.</description>
        <time_frame>Week 4 Time Point</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zylet</title>
            <description>Subject randomized to this arm will be treated with Zylet, twice a day, for 4 weeks. Zylet is a combination of loteprednol and tobramycin. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation. Tobramycin is an antibiotic.
Loteprednol/tobramycin: Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Lotemax</title>
            <description>Subject randomized to this arm will be treated with Lotemax, twice a day, for 4 weeks. Lotemax is also known as loteprednol. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation.
Loteprednol: Eye drops, 1 drop twice a day for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Bausch &amp; Lomb Lubricant Drops</title>
            <description>Subject randomized to this arm will be treated with artificial tears, twice a day, for 4 weeks.
Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops: Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), 1 drop twice a day for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Fluorescein Staining Score</title>
          <description>Corneal Fluorescein Staining is used to assess the level of corneal epitheliopathy that is related to dry eye disease. The CFS scale ranges from 0 to 15 scale, with 0 representing the minimum level of corneal epitheliopathy and 15 representing the maximum level of corneal epitheliopathy.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="4.2"/>
                    <measurement group_id="O2" value="5.0" spread="3.3"/>
                    <measurement group_id="O3" value="4.8" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Zylet</title>
          <description>Subject randomized to this arm will be treated with Zylet, twice a day, for 4 weeks. Zylet is a combination of loteprednol and tobramycin. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation (swelling). Tobramycin is an antibiotic.
Loteprednol/tobramycin: Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Lotemax</title>
          <description>Subject randomized to this arm will be treated with Lotemax, twice a day, for 4 weeks. Lotemax is also known as loteprednol. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation (swelling).
Loteprednol: Eye drops, 1 drop twice a day for 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>Bausch &amp; Lomb Lubricant Drops</title>
          <description>Subject randomized to this arm will be treated with artificial tears, twice a day, for 4 weeks.
Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops: Bausch + Lomb Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), 1 drop twice a day for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Blurriness</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blurriness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title vocab="Excess Tearing">Excess Tearing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title vocab="Redness">Redness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title vocab="Headache">Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title vocab="Dryness">Dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Reza Dana</name_or_title>
      <organization>Massachusetts Eye and Ear</organization>
      <phone>617-573-4431 ext 4431</phone>
      <email>Reza_Dana@meei.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

